PegBio Co., Ltd. — Board/Management Information 2026

Apr 1, 2026

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PegBio Co., Ltd.

派格生物醫藥(杭州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2565)

CHANGE OF JOINT COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

The board (the "Board") of directors (the "Director(s)") of PegBio Co., Ltd. (the "Company") hereby announces that Mr. Chow Shing Lung ("Mr. Chow") has resigned as (i) a joint company secretary of the Company (the "Joint Company Secretary"); (ii) an authorised representative of the Company ("Authorised Representative") under the Rule 3.05 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange"); and (iii) the representative for acceptance of service of process and notices on behalf of the Company in Hong Kong (the "Process Agent") under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from 1 April 2026.

Mr. Chow confirmed that he has no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company and the Stock Exchange in relation to his resignation.

The Board further announces that, following Mr. Chow's resignation as a Joint Company Secretary, Authorised Representative and the Process Agent, Ms. Kwok Yan Ting Jennis ("Ms. Kwok") has been appointed as a Joint Company Secretary, Authorised Representative and the Process Agent with effect from 1 April 2026. Mr. Huang Yifeng ("Mr. Huang") will continue to act as the other Joint Company Secretary.

The biographical details of Ms. Kwok and Mr. Huang are as follows:

Ms. Kwok

Ms. Kwok has over 12 years of extensive experience in corporate governance, company secretarial practice and regulatory compliance. She is currently Senior Manager, Entity Solutions of Computershare Hong Kong Investor Services Limited.

Ms. Kwok holds a degree of Bachelor of Business Administration from Hong Kong Shue Yan University. She is a fellow member of both The Hong Kong Chartered Governance Institute (the "HKCGI") and The Chartered Governance Institute in the United Kingdom, and she is also a holder of the practitioner's endorsement of HKCGI. In addition, she is a Certified Environmental, Social and Governance Analyst (CESGA®) accredited by The European Federation of Financial

---

Analysts Societies (EFFAS) and a Certified ESG Planner (CEP®) awarded by the International Chamber of Sustainable Development (ICSD). She holds the Sustainability and Climate Risk (SCR®) Certificate issued by the Global Association of Risk Professionals (GARP®).

Mr. Huang

Mr. Huang Yifeng (黄一峰), aged 37, is the secretary of the Board and our Joint Company Secretary, and is primarily responsible for business operations, capital management, public relations, investor relations, and company secretarial matters of our Group. Mr. Huang joined our Group in November 2022 as assistant of the Board, and has been serving as the secretary of the Board since May 27, 2023. He was appointed as our Joint Company Secretary in January 2024.

Prior to joining our Group, Mr. Huang served as a manager in Country Garden Holdings Company Limited (碧桂園控股有限公司) (a company listed on the Hong Kong Stock Exchange, stock code: 2007) from July 2015 to April 2016. From May 2016 to December 2017, he served as the general counsel and executive general manager in Shenzhen Qianhai Zhongke Lechuang Fund Management Co., Ltd. (深圳前海中科樂創基金管理有限公司). From January 2018 to February 2019, he served as the vice general manager of legal matters in Kaisa Group Holdings Ltd. (佳兆業集團控股有限公司) (a company listed on the Hong Kong Stock Exchange, stock code: 1638). From February 2019 to November 2020, he worked in Kaisa Health Group Holdings Limited (佳兆業健康集團控股有限公司) (a company listed on the Hong Kong Stock Exchange, stock code: 876) as the general counsel, the head of securities matters, and the fund general manager. From November 2019 to November 2020, Mr. Huang served as the executive director and the general manager in Kaisa Health Equity Fund Management (Guangzhou) Co., Ltd. (佳兆業健康股權投資基金管理(廣州)有限公司). From November 2020 to April 2022, he served as the secretary to the board of directors in Qinghai Pharmaceutical Co., Ltd. (青海製藥有限公司).

Mr. Huang received his bachelor's degree in law in June 2009 from Shenzhen University (深圳大學) in the PRC, and his master's degree in law in March 2012 from Hosei University in Japan. Mr. Huang also completed his doctoral courses in law in March 2018 from Hosei University in Japan. Mr. Huang was granted (i) the qualification of secretary to the board of directors by the Shenzhen Stock Exchange in September 2020, (ii) the legal professional qualification by the Ministry of Justice of the PRC (中華人民共和國司法部) in March 2013, and (iii) the fund practicing qualification by the Asset Management Association of China (中國證券投資基金業協會) in December 2015.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

References are made to the waivers (the "Original Waivers") granted to the Company by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules in relation to the eligibility of Mr. Huang to act as a Joint Company Secretary for a period of three years starting from the date on which the H shares of the Company were first listed and dealings therein were first permitted to take place on the Main Board of the Stock Exchange (i.e. 27 May 2025) (the "Original Waiver Period"), on the condition that (i) Mr. Huang must be assisted by Ms. Chan Yuen Mui ("Ms. Chan") or Mr. Chow (as the case may be) as a Joint Company Secretary during the Original Waiver Period to enable him to acquire relevant experience (as defined in Note 2 to Rule 3.28 of the Listing Rules), in order to discharge his duties under the position of a Joint Company Secretary. Relevant details of the Original Waivers were disclosed in the Company's prospectus dated 19 May 2025 and announcement dated 26 August 2025.

---

In view of Mr. Chow's resignation, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a new waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules with respect to the eligibility of Mr. Huang to act as a Joint Company Secretary (the "New Waiver") from 1 April 2026 (i.e. from the effective date of Ms. Kwok's appointment as a Joint Company Secretary) to 26 May 2028 (i.e. the remaining period of the Original Waivers) (the "Remaining Waiver Period"). The New Waiver has been granted on the following conditions:

(i) Mr. Huang must be assisted by Ms. Kwok during the Remaining Waiver Period; and
(ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Remaining Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Mr. Huang, having had the benefit of Ms. Chan, Mr. Chow and Ms. Kwok's assistance for approximately three years, has attained the relevant experience and is capable of discharging the functions of a company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the New Waiver if the Company's situation changes.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Chow for his valuable contribution and services to the Company during his tenure of office, and welcome Ms. Kwok for her new appointment as our Joint Company Secretary, Authorised Representative, and the Process Agent.

By order of the Board

PegBio Co., Ltd.

派格生物醫藥(杭州)股份有限公司

Michael Min XU

Chairman of the Board, Executive Director

and General Manager

Hangzhou, the PRC, 1 April 2026

As of the date of this announcement, the board of directors of the Company comprises: (i) Dr. Michael Min XU and Ms. Xiaojun WANG as executive directors; (ii) Dr. Xiangjun ZHOU, Dr. Yuhong XU, Ms. Ting ZHAI and Mr. Hongkai LI as non-executive directors; and (iii) Dr. Jiancun ZHANG, Dr. Yangyang CHEN and Ms. Xinpeng FAN as independent non-executive directors.

3